Company intelligence / Profile preview

Flen Health

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Flen Health has a strong commercial presence with established products like Flamigel® and Flaminal®, which are widely used in over 30 countries. Their latest innovation, VES 0—an enhancement of the Flaminal® technology—has shown promising preclinical results and will enter Phase 0 clinical trials soon. The company’s enzyme/protein platforms are recognized for their effectiveness in difficult-to-heal wounds and have received significant external R&D funding.

Therapeutic areas: Dermatology
Modalities: Enzyme-based biopharmaceuticalsprotein-based treatmentssmall molecules
Industry: Therapeutic Medical Devices

Drug pipeline

5 assets

Flaminal

Commercial

Indications: Acute wounds, Chronic wounds

4 more assets in the full pipeline.

Partnerships

Collaborations with academic institutions and non-academic partners across EuropeEU Innovation Company Label recipient

Beyond the preview

Go deeper on Flen Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flen Health.